nach oben

Clinical Rheumatology

Erschienen in:

13.08.2020 | Original Article

The effectiveness of treatments for patients with SAPHO syndrome: a follow-up study of 24 cases from a single center and review of literature

verfasst von: Hong Huang, Zhuoli Zhang, Juan Zhao, Yanjie Hao, Wei Zhou

Erschienen in: Clinical Rheumatology | Ausgabe 3/2021

Einloggen, um Zugang zu erhalten

Abstract

Objectives

To evaluate the effectiveness of current treatments for SAPHO syndrome (synovitis, acne, pustulosis, hyperostosis, and osteitis) by delineating the therapeutic choices and the outcome of patients in a medical center of China and review of the literature.

Method

An observational study was performed on patients diagnosed as SAPHO syndrome in the Peking University First Hospital from 2009 to 2015. Clinical data including osteoarticular and cutaneous manifestations, laboratory and medical imaging findings, treatments, and outcomes were analyzed retrospectively. A literature detailing the usage of medicines and SAPHO syndrome patient responses to treatment were selected.

Results

Clinical data of 24 patients were analyzed in this study. The mean age was 42.4 ± 15.5 years old at the time of diagnosis. Of a total of 17 patients that received the combination treatments of NSAIDs and DMARDs, 15 of them experienced an improvement in their symptoms. Bisphosphonates were given to 18 patients. Four patients were treated with TNF blockers, and one of them had adalimumab ineffective and then improved by add-on of DMARDs. The mean follow-up period was 2.5 years. Twenty-one patients (87.5%) had a favorable outcome and exhibited improved disease condition in the last follow-up.

Conclusions

The majority of patients with SAPHO syndrome respond well to combination therapy of NSAIDs, DMARDs, and bisphosphonates. TNF blockers are effective in a patient refractory to NSAID and DMARDs. However, in case TNF blockers are ineffective, add-on of DMARDs may be effective. Thus, the proper application of conventional DMARDs is still worth a position in the treatment of SAPHO syndrome.

Key Points

•NSAIDs and DMARDs and/or bisphosphonates can alleviate symptoms of the majority of patients with SAPHO syndrome.

•TNF blockers are effective in patients who do not respond well to NSIADs and DMARDs.

•In case TNF blockers are ineffective, add-on of conventional DMARDs may be effective.

Nur mit Berechtigung zugänglich

Witt M, Meier J, Hammitzsch A, Proft F, Schulze-Koops H, Grunke M (2014) Disease burden, disease manifestations and current treatment regimen of the SAPHO syndrome in Germany: results from a nationwide patient survey. Semin Arthritis Rheum 43(6):745–750. https://doi.org/10.1016/j.semarthrit.2013.10.010CrossRefPubMed

Rohekar G, Inman RD (2006) Conundrums in nosology: synovitis, acne, pustulosis, hyperostosis, and osteitis syndrome and spondylarthritis. Arthritis Rheum 55(4):665–669. https://doi.org/10.1002/art.22087CrossRefPubMed

Dumolard A, Gaudin P, Juvin R, Bost M, Peoc’h M, Phelip X (1999) SAPHO syndrome or psoriatic arthritis? A familial case study. Rheumatology (Oxford, England) 38(5):463–467. https://doi.org/10.1093/rheumatology/38.5.463CrossRef

Aljuhani F, Tournadre A, Tatar Z, Couderc M, Mathieu S, Malochet-Guinamand S, Soubrier M, Dubost JJ (2015) The SAPHO syndrome: a single-center study of 41 adult patients. J Rheumatol 42(2):329–334. https://doi.org/10.3899/jrheum.140342CrossRefPubMed

Kahn MF, Khan MA (1994) The SAPHO syndrome. Baillieres Clin Rheumatol 8(2):333–362. https://doi.org/10.1016/s0950-3579(94)80022-7CrossRefPubMed

Mateo L, Sanint J, Rodríguez Muguruza S, Martínez Morillo M, Pérez Andrés R, Domenech Puigcerver S (2017) SAPHO syndrome presenting as an osteolytic lesion of the neck. Reumatol Clin 13(1):44–47. https://doi.org/10.1016/j.reuma.2015.11.016CrossRefPubMed

Takigawa T, Tanaka M, Nakahara S, Sugimoto Y, Ozaki T (2008) SAPHO syndrome with rapidly progressing destructive spondylitis: two cases treated surgically. Eur Spine J 2(Suppl 2):S331–S337. https://doi.org/10.1007/s00586-008-0663-4CrossRef

Rukavina I (2015) SAPHO syndrome: a review. J Child Orthop 9(1):19–27. https://doi.org/10.1007/s11832-014-0627-7CrossRefPubMedPubMedCentral

Hayem G, Bouchaud-Chabot A, Benali K, Roux S, Palazzo E, Silbermann-Hoffman O, Kahn MF, Meyer O (1999) SAPHO syndrome: a long-term follow-up study of 120 cases. Semin Arthritis Rheum 29(3):159–171. https://doi.org/10.1016/s0049-0172(99)80027-4CrossRefPubMed

10.

Earwaker JW, Cotten A (2003) SAPHO: syndrome or concept? Imaging findings. Skelet Radiol 32(6):311–327. https://doi.org/10.1007/s00256-003-0629-xCrossRef

11.

Ichikawa J, Sato E, Haro H, Ando T, Maekawa S, Hamada Y (2009) Successful treatment of SAPHO syndrome with an oral bisphosphonate. Rheumatol Int 29(6):713–715. https://doi.org/10.1007/s00296-008-0760-zCrossRefPubMed

12.

Sabugo F, Liberman C, Niedmann JP, Soto L, Cuchacovich M (2008) Infliximab can induce a prolonged clinical remission and a decrease in thyroid hormonal requirements in a patient with SAPHO syndrome and hypothyroidism. Clin Rheumatol 27(4):533–535. https://doi.org/10.1007/s10067-007-0767-yCrossRefPubMed

13.

Court C, Charlez C, Molina V, Clerc D, Miquel A, Nordin JY (2005) Isolated thoracic spine lesion: is this the presentation of a SAPHO syndrome? A case report. Eur Spine J 14(7):711–715. https://doi.org/10.1007/s00586-004-0791-4CrossRefPubMed

14.

Skoura E, Giannopoulou C, Zaromytidou E, Pianou N, Houssianakou I (2007) A case of non-malignant multifocal lesions on the methyl diphosphonate technetium-99m bone scan with enteropathy. SAPHO syndrome. Hellenic J Nucl Med 10(1):26–28

15.

Galadari H, Bishop AG, Venna SS, Sultan E, Do D, Zeltser R (2009) Synovitis, acne, pustulosis, hyperostosis, and osteitis syndrome treated with a combination of isotretinoin and pamidronate. J Am Acad Dermatol 61(1):123–125. https://doi.org/10.1016/j.jaad.2008.10.046CrossRefPubMed

16.

Soyfoo MS, Gangji V, Margaux J (2010) Successful treatment of SAPHO syndrome with ibandronate. J Clin Rheumatol 16(5):253. https://doi.org/10.1097/RHU.0b013e3181e9be89CrossRefPubMed

17.

Just A, Adams S, Brinkmeier T, Barsegian V, Lorenzen J, Schilling F, Frosch P (2008) Successful treatment of primary chronic osteomyelitis in SAPHO syndrome with bisphosphonates. Journal der Deutschen Dermatologischen Gesellschaft 6(8):657–660. https://doi.org/10.1111/j.1610-0387.2008.06588.xCrossRefPubMed

18.

Spyridonidis T, Giannakenas C, Papandrianos N, Barla P, Apostolopoulos DJ (2007) Two cases of synovitis, acne, pustulosis, osteitis--SAPHO syndrome. Hellenic J Nucl Med 10(2):109–112

19.

Amital H, Applbaum YH, Aamar S, Daniel N, Rubinow A (2004) SAPHO syndrome treated with pamidronate: an open-label study of 10 patients. Rheumatology (Oxford, England) 43(5):658–661. https://doi.org/10.1093/rheumatology/keh149CrossRef

20.

Courtney PA, Hosking DJ, Fairbairn KJ, Deighton CM (2002) Treatment of SAPHO with pamidronate. Rheumatology (Oxford, England) 41(10):1196–1198. https://doi.org/10.1093/rheumatology/41.10.1196CrossRef

21.

Zwaenepoel T, Vlam K (2016) SAPHO: treatment options including bisphosphonates. Semin Arthritis Rheum 46(2):168–173. https://doi.org/10.1016/j.semarthrit.2016.04.004CrossRefPubMed

22.

Susanto CR, Nanayakkara PW (2003) The skin is the clue. Eur J Intern Med 14(8):493–494. https://doi.org/10.1016/j.ejim.2003.08.005CrossRefPubMed

23.

Wagner AD, Andresen J, Jendro MC, Hülsemann JL, Zeidler H (2002) Sustained response to tumor necrosis factor alpha-blocking agents in two patients with SAPHO syndrome. Arthritis Rheum 46(7):1965–1968. https://doi.org/10.1002/art.10539CrossRefPubMed

24.

Kim CH, Kadhim S, Julien C (2014) Treatment of pain in SAPHO (synovitis, acne, pustulosis, hyperostosis, and osteitis) syndrome. PM & R 6(1):92–95. https://doi.org/10.1016/j.pmrj.2013.08.610CrossRef

25.

Ben Abdelghani K, Dran DG, Gottenberg JE, Morel J, Sibilia J, Combe B (2010) Tumor necrosis factor-alpha blockers in SAPHO syndrome. J Rheumatol 37(8):1699–1704. https://doi.org/10.3899/jrheum.091086CrossRefPubMed

26.

Colina M, Govoni M, Orzincolo C, Trotta F (2009) Clinical and radiologic evolution of synovitis, acne, pustulosis, hyperostosis, and osteitis syndrome: a single center study of a cohort of 71 subjects. Arthritis Rheum 61(6):813–821. https://doi.org/10.1002/art.24540CrossRefPubMed

27.

Kamata Y, Minota S (2015) Successful treatment of a patient with SAPHO syndrome with certolizumab pegol. Rheumatol Int 35(9):1607–1608. https://doi.org/10.1007/s00296-015-3263-8CrossRefPubMed

28.

Pottecher P, Loffroy R, Estivalet L, Thouant P, Ornetti P, Ricolfi F, Krausé D (2014) SAPHO syndrome revealed by sclerosing mandibular osteomyelitis. Diagn Intervent Imaging 95(9):885–887. https://doi.org/10.1016/j.diii.2014.02.004CrossRef

29.

Ornetti P, Pottecher P (2014) Clinical images: refractory SAPHO syndrome involving the mandible. Arthritis Rheumatol (Hoboken, NJ) 66(7):1966. https://doi.org/10.1002/art.38632CrossRef

30.

Marí A, Morla A, Melero M, Schiavone R, Rodríguez J (2014) Diffuse sclerosing osteomyelitis (DSO) of the mandible in SAPHO syndrome: a novel approach with anti-TNF therapy. Systematic review. J Craniomaxillofac Surg 42(8):1990–1996. https://doi.org/10.1016/j.jcms.2014.09.004CrossRefPubMed

31.

Arias-Santiago S, Sanchez-Cano D, Callejas-Rubio JL, Fernández-Pugnaire MA, Ortego-Centeno N (2010) Adalimumab treatment for SAPHO syndrome. Acta Derm Venereol 90(3):301–302. https://doi.org/10.2340/00015555-0822CrossRefPubMed

32.

Eleftheriou D, Gerschman T, Sebire N, Woo P, Pilkington CA, Brogan PA (2010) Biologic therapy in refractory chronic non-bacterial osteomyelitis of childhood. Rheumatology (Oxford, England) 49(8):1505–1512. https://doi.org/10.1093/rheumatology/keq122CrossRef

33.

Rosero A, Ruano R, Martin M, Hidalgo C, Garcia-Talavera J (2013) Acute venous thrombosis as complication and clue to diagnose a SAPHO syndrome case. A case report. Acta Reumatol Port 38(3):203–206PubMed

34.

Hayem G (2004) SAPHO syndrome. La Revue du Praticien 54(15):1635–1636PubMed

35.

Qiu D, Kao PN (2003) Immunosuppressive and anti-inflammatory mechanisms of triptolide, the principal active diterpenoid from the Chinese medicinal herb Tripterygium wilfordii Hook. f. Drugs R&D 4(1):1–18. https://doi.org/10.2165/00126839-200304010-00001CrossRef

36.

Li C, Sun X, Cao Y, Xu W, Zhang W, Dong Z (2017) Case report: remarkable remission of SAPHO syndrome in response to Tripterygium wilfordii hook f treatment. Medicine 96(47):e8903. https://doi.org/10.1097/md.0000000000008903CrossRefPubMedPubMedCentral

37.

Assmann G, Kueck O, Kirchhoff T, Rosenthal H, Voswinkel J, Pfreundschuh M, Zeidler H, Wagner AD (2009) Efficacy of antibiotic therapy for SAPHO syndrome is lost after its discontinuation: an interventional study. Arthritis Res Ther 11(5):R140. https://doi.org/10.1186/ar2812CrossRefPubMedPubMedCentral

38.

Eyrich GK, Langenegger T, Bruder E, Sailer HF, Michel BA (2000) Diffuse chronic sclerosing osteomyelitis and the synovitis, acne, pustolosis, hyperostosis, osteitis (SAPHO) syndrome in two sisters. Int J Oral Maxillofac Surg 29(1):49–53CrossRef

39.

Li C, Zhao Y, Zuo Y, Zhou Y, Zhang F, Liu S, Zhu Q, Chen J, Zhang W, Xu W, Gu Z, Li L, Li F, Tao W, Cao Y, Sun X, Jing H, Chen H, Zhang S, Dong Z, Liu J, Shi X, Hao W, Qiu G, Zhang W, Wu N, Wu Z (2019) Efficacy of bisphosphonates in patients with synovitis, acne, pustulosis, hyperostosis, and osteitis syndrome: a prospective open study. Clin Exp Rheumatol 37(4):663–669PubMed

Titel: The effectiveness of treatments for patients with SAPHO syndrome: a follow-up study of 24 cases from a single center and review of literature
verfasst von: Hong Huang
Zhuoli Zhang
Juan Zhao
Yanjie Hao
Wei Zhou
Publikationsdatum: 13.08.2020
Verlag: Springer International Publishing
Erschienen in: Clinical Rheumatology / Ausgabe 3/2021
Print ISSN: 0770-3198
Elektronische ISSN: 1434-9949
DOI: https://doi.org/10.1007/s10067-020-05322-x

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

17.04.2024 | DGIM 2024 | Nachrichten

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

The effectiveness of treatments for patients with SAPHO syndrome: a follow-up study of 24 cases from a single center and review of literature

Abstract

Objectives

Method

Results

Conclusions

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Denken Sie bei starker Blutung auch an die Hemmkörper-Hämophilie

Adjuvante Brustkrebstherapie: Doppelt hält besser

Delir kann Demenz begünstigen

Vorsicht mit hohen NSAR-Dosen bei ankylosierender Spondylitis!

Update Innere Medizin

Springer Medizin

Abstract

Objectives

Method

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2021

Myositis-specific autoantibodies in adults with idiopathic inflammatory myopathy: correlations with diagnosis and disease activity

Dose tapering of biologic agents in patients with rheumatoid arthritis—results from a cohort study in Germany

Two sides on the fibromyalgia coin: physical pain and social pain (invalidation)

Ultrasound measurement of muscle thickness at the anterior thigh level in rheumatology setting: a reliability study.

Hierarchical cluster analysis of cytokine profiles reveals a cutaneous vasculitis-associated subgroup in dermatomyositis

Sentinel joint scoring in rheumatoid arthritis: an individualized power Doppler assessment strategy

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Denken Sie bei starker Blutung auch an die Hemmkörper-Hämophilie

Adjuvante Brustkrebstherapie: Doppelt hält besser

Delir kann Demenz begünstigen

Vorsicht mit hohen NSAR-Dosen bei ankylosierender Spondylitis!

Update Innere Medizin